INT8086

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1987
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 24
Total Number 24
Disease Relevance 3.31
Pain Relevance 12.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Npy) extracellular region (Npy)
Anatomy Link Frequency
hypothalamus 4
neurons 4
nucleus 4
nerve 2
medulla oblongata 2
Npy (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Neuropeptide 94 100.00 Very High Very High Very High
gABA 16 100.00 Very High Very High Very High
Desipramine 14 100.00 Very High Very High Very High
fluoxetine 23 99.98 Very High Very High Very High
Clonidine 14 99.98 Very High Very High Very High
antagonist 17 99.96 Very High Very High Very High
agonist 16 99.96 Very High Very High Very High
noradrenaline 20 99.90 Very High Very High Very High
guanethidine 7 99.84 Very High Very High Very High
Endogenous opioid 3 99.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Aids-related Complex 1 99.66 Very High Very High Very High
Hypertension 10 99.56 Very High Very High Very High
Obesity 37 98.68 Very High Very High Very High
Bordatella Infection 4 98.56 Very High Very High Very High
Stress 2 97.62 Very High Very High Very High
Appetite Loss 7 93.28 High High
Hypoglycemia 2 92.72 High High
Eating Disorder 4 91.72 High High
Diabetes Mellitus 4 90.16 High High
Hyperphagia 7 82.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Desipramine suppressed the NPY-LI release induced by tyramine apparently by the inhibition of the uptake of tyramine is suggested by the significant positive correlation between the reduction of 14C-tyramine uptake and the inhibition of NPY-LI release induced by desipramine (r = 0.946).
Negative_regulation (inhibition) of Localization (release) of NPY associated with desipramine
1) Confidence 0.59 Published 1987 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 3108675 Disease Relevance 0 Pain Relevance 0.26
We have used the procedure to show that anaesthesia dramatically decreased NPY release, while a 48 h period of food deprivation significantly increased extracellular NPY concentrations.
Negative_regulation (decreased) of Localization (release) of NPY
2) Confidence 0.59 Published 1994 Journal Brain Res. Section Abstract Doc Link 7804826 Disease Relevance 0.24 Pain Relevance 0.08
Additionally, AM251 administered alone, in the absence of exogenous cannabinoid agonists, inhibited NPY release demonstrating the role of endogenous cannabinoids in NPY release.
Negative_regulation (inhibited) of Localization (release) of NPY associated with cannabinoid and agonist
3) Confidence 0.43 Published 2005 Journal Neuropharmacology Section Abstract Doc Link 15949823 Disease Relevance 0 Pain Relevance 0.61
AM251, a cannabinoid receptor antagonist, blocked the augmentation of NPY release elicited by AEA and CP55,940.
Negative_regulation (blocked) of Localization (release) of NPY associated with cannabinoid receptor and antagonist
4) Confidence 0.43 Published 2005 Journal Neuropharmacology Section Abstract Doc Link 15949823 Disease Relevance 0 Pain Relevance 0.61
The alpha 2 agonist clonidine decreased evoked release of NPY, while the alpha 2 antagonist yohimbine increased the potassium-evoked release.
Negative_regulation (decreased) of Localization (release) of NPY associated with antagonist, agonist and clonidine
5) Confidence 0.43 Published 1993 Journal Neuropharmacology Section Abstract Doc Link 8413845 Disease Relevance 0 Pain Relevance 0.51
Prazosin decreased both the basal and potassium-evoked release of NPY.
Negative_regulation (decreased) of Localization (release) of NPY
6) Confidence 0.43 Published 1993 Journal Neuropharmacology Section Abstract Doc Link 8413845 Disease Relevance 0 Pain Relevance 0.49
Propranolol had the most profound effect on release of NPY, causing a significant decrease in basal release and a large decrease in the potassium-evoked release of NPY from slices of hypothalamus.
Negative_regulation (decrease) of Localization (release) of NPY in hypothalamus
7) Confidence 0.43 Published 1993 Journal Neuropharmacology Section Abstract Doc Link 8413845 Disease Relevance 0 Pain Relevance 0.45
We conclude that fluoxetine inhibits various aspects of the activity of the neuropeptide Yergic arcuato-paraventricular neurons, and suggest that reduced neuropeptide Y release in the paraventricular nucleus may mediate, at least in part, the drug's hypophagic action.
Negative_regulation (reduced) of Localization (release) of neuropeptide Y in nucleus associated with neuropeptide and fluoxetine
8) Confidence 0.43 Published 1996 Journal Neuroscience Section Abstract Doc Link 8737424 Disease Relevance 0.44 Pain Relevance 0.96
We conclude that the adrenergic stress reaction in response to tracheal intubation in children was short-lived and of limited magnitude, as indicated by the lack of NPY release.
Negative_regulation (lack) of Localization (release) of NPY associated with stress
9) Confidence 0.43 Published 1999 Journal Br J Anaesth Section Abstract Doc Link 10434822 Disease Relevance 0.17 Pain Relevance 0.33
Desipramine suppressed the NPY-LI release induced by tyramine apparently by the inhibition of the uptake of tyramine is suggested by the significant positive correlation between the reduction of 14C-tyramine uptake and the inhibition of NPY-LI release induced by desipramine (r = 0.946).
Negative_regulation (suppressed) of Localization (release) of NPY associated with desipramine
10) Confidence 0.43 Published 1987 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 3108675 Disease Relevance 0 Pain Relevance 0.27
On the other hand, the inhibition of cAMP accumulation by the alpha 2-adrenergic agonist clonidine decreased NPY secretion.
Negative_regulation (decreased) of Localization (secretion) of NPY associated with agonist and clonidine
11) Confidence 0.42 Published 1993 Journal Endocrinology Section Abstract Doc Link 8396008 Disease Relevance 0.16 Pain Relevance 0.21
However, 0.1mg/kg reserpine reduced both the content and release of NA but decreased only the content but not the release of ir-NPY; the rise in perfusion pressure was halved.
Negative_regulation (decreased) of Localization (release) of NPY associated with noradrenaline
12) Confidence 0.42 Published 2002 Journal Peptides Section Abstract Doc Link 12217427 Disease Relevance 0 Pain Relevance 0.61
There was a positive correlation between the inhibitory effect of desipramine on the NPY release and on the uptake of [14C]tyramine into synaptosomes.
Negative_regulation (effect) of Localization (release) of NPY associated with desipramine
13) Confidence 0.41 Published 1987 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3595714 Disease Relevance 0 Pain Relevance 0.39
Push-pull sampling in lean and fatty Zucker rats showed that neuropeptide Y secretion in the paraventricular nucleus was significantly reduced after acute fluoxetine treatment.
Negative_regulation (reduced) of Localization (secretion) of neuropeptide Y in nucleus associated with neuropeptide and fluoxetine
14) Confidence 0.38 Published 1996 Journal Neuroscience Section Abstract Doc Link 8737424 Disease Relevance 0.48 Pain Relevance 1.13
The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats.
Negative_regulation (reduces) of Localization (secretion) of neuropeptide Y in hypothalamus associated with obesity, neuropeptide and fluoxetine
15) Confidence 0.38 Published 1996 Journal Neuroscience Section Title Doc Link 8737424 Disease Relevance 0.33 Pain Relevance 0.85
In aged male rats, due to the inability of hypothalamic NPY neurons to respond appropriately to the trophic effects of androgens, NPY neurosecretion is diminished.
Negative_regulation (diminished) of Localization (neurosecretion) of NPY in neurons
16) Confidence 0.37 Published 1992 Journal Front Neuroendocrinol Section Abstract Doc Link 1361458 Disease Relevance 0 Pain Relevance 0.17
The inhibitory effect of rimonabant was also prevented by naloxone and a kappa-opioid receptor selective antagonist, suggesting that GABA release from arcuate NPY/AgRP/GABA neurones can be inhibited by endogenous opioid peptides, and that the release of opioid peptides is sensitive to cannabinoids.
Negative_regulation (inhibited) of Localization (release) of NPY associated with gaba, cannabinoid, antagonist, endogenous opioid, kappa opioid receptor, narcan and opioid
17) Confidence 0.37 Published 2010 Journal J. Neuroendocrinol. Section Abstract Doc Link 20236227 Disease Relevance 0 Pain Relevance 1.54
These data suggest that tyramine enters into nerve terminals through a desipramine-sensitive mechanism, resulting in the co-release of NE and NPY which can be reduced by guanethidine.
Negative_regulation (reduced) of Localization (release) of NPY in nerve associated with desipramine and guanethidine
18) Confidence 0.35 Published 1987 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3595714 Disease Relevance 0 Pain Relevance 0.38
Guanethidine, however, at a concentration insufficient to block the uptake of tyramine reduced the release of both NE and NPY.
Negative_regulation (reduced) of Localization (release) of NPY associated with guanethidine
19) Confidence 0.35 Published 1987 Journal Eur. J. Pharmacol. Section Abstract Doc Link 3595714 Disease Relevance 0 Pain Relevance 0.39
The blockade of alpha 2-adrenergic receptors by RX 781,094 diminished inhibitory effects of neuropeptide Y on norepinephrine release.
Negative_regulation (diminished) of Localization (release) of neuropeptide Y associated with neuropeptide
20) Confidence 0.35 Published 1990 Journal Hypertension Section Abstract Doc Link 1972138 Disease Relevance 0.31 Pain Relevance 0.78

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox